Djibouti vs United States of America: Protecting minority investors: Ease of shareholder suits index (0-10)
Protecting minority investors: Ease of shareholder suits index (0-10) over time
- Djibouti
- United States of America
How they compare
Djibouti currently reports 100 against 90 in United States of America, a difference of 10.
That makes Djibouti's figure about 1.1 times United States of America's.
The two have swapped places 1 time across 7 shared years of data; in 2013 it was United States of America ahead.
Djibouti ranks 1st and United States of America ranks 2nd of 191 countries.
United States of America has averaged higher in every one of the 1 decades both report.
Frequently asked questions
- Which has higher protecting minority investors: ease of shareholder suits index (0-10), Djibouti or United States of America?
- Djibouti, at 100 against 90 in United States of America as of 2019.
- What is the difference in protecting minority investors: ease of shareholder suits index (0-10) between Djibouti and United States of America?
- 10, with Djibouti ahead.
- How many years of comparable data are there for Djibouti and United States of America?
- 7 years are reported by both, from 2013 to 2019.
- How do Djibouti and United States of America rank globally for protecting minority investors: ease of shareholder suits index (0-10)?
- Djibouti ranks 1st and United States of America ranks 2nd of 191 countries.
- Where does this data come from?
- The World Bank, published as Protecting minority investors: Ease of shareholder suits index (0-10) (DB15-20 methodology) - Score. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The score for ease of shareholder suits index benchmarks economies with respect to the regulatory best practice on the indicator. The score is indicated on a scale from 0 to 100, where 0 represents the worst regulatory performance and 100 the best regulatory performance, and is computed based on the methodology in the DB15-20 studies.